Ophthalmic Business News

The FDA approved the iDose TR for the lowering of IOP in patients with ocular hypertension or open-angle glaucoma, according to a press release from Glaukos.

The FDA granted 510(k) clearance for the Eagle device, a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG glaucoma laser for selective laser trabeculoplasty, according to a press release from Belkin Vision.

As we approach the year end, many investors, including physicians, will review their portfolios and assess the last 12 months of performance.

SAN FRANCISCO — Ophthalmologists need to work with industry to reduce the carbon footprint created by medical products, according to a speaker at the American Academy of Ophthalmology meeting.

Historically in the United States, Medicare has not had the legal authority to negotiate the prices of drugs. Essentially, drug prices were unregulated.

Atsena Therapeutics reported positive 12-month safety and efficacy data from a phase 1/2 trial of ATSN-101 gene therapy in GUCY2D-associated Leber congenital amaurosis.

The phase 2 DAVIO 2 trial of EYP-1901 met all primary and secondary endpoints in patients with wet age-related macular degeneration, EyePoint Pharmaceuticals announced in a press release.

Healio’s top video perspectives from Eyecelerator@AAO include a key update on sozinibercept for neovascular age-related macular degeneration and a launch announcement for the ZeptoLink IOL positioning system.

Harrow announced an early completed transfer of the new drug application for Triesence, a synthetic corticosteroid for treatment of several inflammatory ophthalmic conditions, including those not responsive to topical corticosteroids.

Positive safety and tolerability data were reported for OLX10212, a small interfering RNA technology, in patients with neovascular age-related macular degeneration, according to a press release from OliX Pharmaceuticals.